Add 2 More Reports For 20% off

Report Overview

The sickle cell disease treatment market was valued at USD 5.38 billion in 2023 driven by the rising prevalence of sickle cell disease and advancements in treatment options across the 8 major markets. It is expected to grow at a CAGR of 16.9% during the forecast period 2024-2032 and attain a market value of USD 21.92 billion by 2032.

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Sickle Cell Disease Treatment Market Outlook

  • CDC's May  2024 report states that sickle cell disease impacts around 100,000 people in the United States. The increasing prevalence of sickle cell disease is expected to fuel market demand in the coming years. 
  • In December  2023, the FDA approved Casgevy and Lyfgenia as the first cell-based gene therapies for sickle cell disease in patients 12 years and older. The rising development of such innovative treatments is poised to boost the market growth.
  • The strong regulatory support from health authorities and ongoing research and development efforts are likely to elevate the market value. 

Sickle Cell Disease Treatment Market Overview

Treatment for sickle cell disease (SCD) aims to address symptoms such as anemia, pain, and organ damage. Sickle cell disease is a hereditary blood condition characterized by the presence of abnormal hemoglobin S that creates stiff, sickle-shaped red blood cells, resulting in obstruction and decreased oxygen supply to tissues. Mutations in the HBB gene result in deformed red blood cells, leading to aggregation and obstruction in blood vessels. 

Managing sickle cell disease requires a comprehensive strategy that includes medication, blood transfusions, pain relief, and possible cures such as bone marrow transplants and new gene therapies. Patients frequently experience multiple hospital stays and need ongoing care to address the symptoms and complications linked to the illness.

In complicated cases of sickle cell disease, bone marrow or stem cell transplants may be needed for potential treatments. New possibilities are presented by emerging treatments such as gene therapies, voxelotor, and crizanlizumab. Several factors such as the rising patient population, significant investment from pharmaceutical companies, and an increasing focus on targeted therapies are likely to positively influence the market dynamics in the coming years.

Sickle Cell Disease Treatment Market Growth Drivers

Increasing Prevalence of Sickle Cell Disease Drives Market Growth

The increasing occurrence of sickle cell disease is fueling expansion in the market. Developed countries such as the United States and Europe also experience substantial occurrences because of migration and diversity. The Centers for Disease Control and Prevention’s May  2024 report states that sickle cell disease impacts around 100,000 people in the United States, out of which over 90% are non-Hispanic Black/African Americans and 3%-9% are Hispanics/Latinos. Life expectancy for those with sickle cell disease in the US is 20 years less than average. The need for innovative therapies and long-term care is growing due to the rising impact of the disease on children and adolescents, which is expected to lead to an increased demand for effective treatments.

Advancements in Gene Therapy and Technology are Likely to Boost Sickle Cell Disease Treatment Market Demand

Advancements in gene therapy and gene-editing techniques such as CRISPR-Cas9 are revolutionizing the treatment of sickle cell disease. In December  2023, the FDA approved Casgevy and Lyfgenia as the first cell-based gene therapies for sickle cell disease in patients 12 years and older. Casgevy also marks the first FDA-approved treatment utilizing novel genome editing technology. These treatments provide the potential for a permanent cure by altering or substituting the faulty hemoglobin gene. LentiGlobin and CRISPR-based treatments offer hope for patients with sickle cell disease with promising outcomes. With gene therapy becoming more available, the market is forecasted to expand quickly.

Sickle Cell Disease Treatment Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Shift Toward Curative Therapies

The market for treating sickle cell disease is moving towards curative methods such as stem cell transplantation instead of focusing on managing symptoms. Research is also exploring bone marrow and stem cell transplants as potential cures, despite obstacles such as limited donor availability. These developments are expected to drive market growth in the forecast period. 

Increased Research on Hemoglobin Modifiers

There is a growing focus on studying hemoglobin modifiers such as voxelotor to change abnormal hemoglobin and decrease the deformation of red blood cells. More research is being done to create enhanced next-generation modifiers with better effectiveness and reduced side effects, broadening treatment choices for those with sickle cell disease. Focusing on modifying hemoglobin provides a less invasive option that is anticipated to make a big impact on the market for treating sickle cell disease, as opposed to gene and cell therapies.

Rising Interest in Combination Therapies

Combination treatments are being widely used in managing sickle cell disease to tackle its intricate characteristics. These treatments, including hydroxyurea, voxelotor, and crizanlizumab, focus on various facets of the illness to decrease vaso-occlusive episodes and lessen organ harm. Pharmaceutical companies are prioritizing clinical trials to investigate the synergistic impacts of these combinations, which is likely to aid in market growth.

Growing Demand for Pain Management Solutions

Effective pain control is essential in managing sickle cell disease as frequent crises result in intense pain. Recent treatments are focused on decreasing the frequency of pain, while non-drug methods like cognitive behavioral therapy are becoming more popular. These ground-breaking treatments are anticipated to have a positive impact on enhancing the clinical outcomes of patients with sickle cell disease.

Sickle Cell Disease Treatment Market Segmentation

Market Breakup by Treatment 

  • Pharmacotherapy 
  • Blood Transfusions 
  • Bone Marrow/ Stem Cell Transplantation 
  • Other Supportive Therapies 

Market Breakup by Disease Type

  • Sickle Cell Anaemia 
  • Sickle Hemoglobin-C Disease 
  • Sickle Beta-Thalassemia  
  • Others 

Market Breakup by End User

  • Hospitals 
  • Specialty Clinics 
  • Ambulatory Surgical Centers 
  • Others

Market Breakup by Region

  • United States 
  • EU-4 and the United Kingdom
    • Germany 
    • France 
    • Italy 
    • Spain 
    • United Kingdom
  • Japan 
  • India  

Sickle Cell Disease Treatment Market Share

Market Segmentation Based on the Treatment to Witness Growth

Based on the treatment, the market is divided into pharmacotherapy, blood transfusions, bone marrow/ stem cell transplantation, and other supportive therapies. Out of these, pharmacotherapy is expected to dominate the market because of its effectiveness, widespread availability, and cost-effectiveness. Medications such as hydroxyurea have been utilized for many years to treat symptoms of sickle cell disease. The management of sickle cell disease still heavily relies on medication, as other more invasive treatments such as bone marrow transplantation have limitations.

Market Share Based on Disease Type

Based on the disease type, the market is segmented into sickle cell anaemia, sickle hemoglobin-C disease, sickle beta-thalassemia, and others. Sickle cell anemia is the most prevalent and serious type of sickle cell disease, impacting many patients. Individuals with this disease deal with serious complications like painful crises and organ damage, leading to the need for extensive medical care.

Sickle Cell Disease Treatment Market Analysis by Region

Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India.

The United States is expected to dominate the market powered by government initiatives such as the National Sickle Cell Disease Program and newborn screening, which have enhanced the ability to diagnose and provide treatment at an early stage. Further, the market growth in the region is propelled by high healthcare spending and support from advocacy groups. 

EU-4 and the United Kingdom are also poised to have a significant market share. Newborn screening and extensive healthcare services support individuals with sickle cell disease in the EU-4 (Germany, France, Italy, Spain) and the United Kingdom. The United Kingdom's NHS provides specialized medical services, as gene therapy research advances.

Additionally, the markets in Japan and India are rapidly expanding. Japan puts more emphasis on studying different genetic disorders and allocates substantial resources into researching gene therapy, while India deals with a high burden of sickle cell disease and works to enhance screening and access to treatment. The rise in strategic collaborations along with significant research funding is predicted to boost the development of India's sickle cell disease market in the forecast period.

Leading Players in the Sickle Cell Disease Treatment Market

The key features of the market report include patent analysis, grant analysis, funding, and investment analysis, clinical trials analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Novartis AG

Novartis AG is a Swiss pharmaceutical corporation that focuses on healthcare, producing prescription and generic drugs, as well as eye care products. Their products treat various diseases such as cancer, cardiovascular conditions, and respiratory illnesses. In April  2024, the FDA approved Novartis' Adakveo to reduce pain events in individuals with sickle cell disease. This medication helps decrease the frequency of vaso-occlusive crises in adults and children over 16 years old.

Bluebird Bio, Inc.

Bluebird Bio, Inc. is a biotechnology company based in Massachusetts. In December  2023, the company received FDA approval for LYFGENIA (lovo-cel) to treat sickle cell disease in patients aged 12 and older with a history of vaso-occlusive events. LYFGENIA is a one-time gene therapy designed to address the root cause of the disease and resolve vaso-occlusive events.

Emmaus Life Sciences, Inc.

Emmaus Life Sciences, Inc. develops treatments for rare diseases. In February  2024, they obtained approval from Puerto Rico's Health Dept. for Endari® (L-glutamine oral powder) to treat sickle cell disease. This achievement is a key step in Emmaus' goal to enhance the quality of life for sickle cell disease patients globally.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a biopharmaceutical company based in Boston, Massachusetts. The company is one of the early adopters of rational drug design. In December  2023, Vertex partnered with CRISPR Therapeutics to gain FDA approval for CASGEVY™, a cell therapy for sickle cell disease. This treatment targets patients over 12 suffering from recurrent crises.

Other players in the market are Pfizer Inc, Bristol Myers Squibb Company, Sangamo Therapeutics Inc, AbbVie Inc, Charles River Laboratories, and AstraZeneca plc. 

Key Questions Answered in the Sickle Cell Disease Treatment Market Report

  • What was the sickle cell disease treatment market value in 2023? 
  • What is the sickle cell disease treatment market forecast outlook for 2024-2032? 
  • What are the regional markets covered in the EMR report?
  • What is the market segmentation based on the treatment? 
  • What is the market segmentation based on the disease type? 
  • What is the market breakup based on end user?
  • What are the major factors aiding the sickle cell disease treatment market demand? 
  • How has the market performed so far and how is it anticipated to perform in the coming years? 
  • What are the major drivers, opportunities, and restraints in the market?  
  • What are the major trends influencing the market?  
  • Which regional market is expected to dominate the market share in the forecast period?  
  • Which country is likely to experience elevated growth during the forecast period?  
  • Who are the key players involved in the sickle cell disease treatment market? 
  • What are the current unmet needs and challenges in the market? 
  • How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Treatment
  • Disease Type
  • End User
  • Region
Breakup by Treatment
  • Pharmacotherapy
  • Blood Transfusions
  • Bone Marrow/ Stem Cell Transplantation
  • Others Supportive Therapies
Breakup by Disease Type
  • Sickle Cell Anaemia
  • Sickle Hemoglobin-C Disease
  • Sickle Beta-Thalassemia
  • Others
Breakup by End User
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Others
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
  • India
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • PESTEL Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Company News and Developments
    • Certifications
Companies Covered
  • Novartis AG
  • Pfizer Inc.
  • Bluebird Bio, Inc.
  • Emmaus Life Sciences, Inc.
  • Bristol Myers Squibb Company
  • Vertex Pharmaceuticals Incorporated
  • Sangamo Therapeutics, Inc.
  • AbbVie Inc.
  • Charles River Laboratories
  • AsraZeneca plc

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,499

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,699

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,599

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,599

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63 287899028, +63 967 048 3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124